Upcoming event
Urology Week 2020
Back

Tag: ADT

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532)

Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer

Effect on survival of ADT alone compared to ADT combined with concurrent RT to the prostate in patients with primary bone metastatic PCa in a prospective randomised clinical trial: data from the HORRAD trial

Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)

Role of Androgen Deprivation Therapy in Early Salvage Radiation Among Patients With Prostate-Specific Antigen Level of 0.5 or Less